A share price of Orchestra BioMed Holdings Inc [OBIO] is currently trading at $4.42, up 7.80%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OBIO shares have gain 12.76% over the last week, with a monthly amount glided 24.16%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Orchestra BioMed Holdings Inc [NASDAQ: OBIO] stock has seen the most recent analyst activity on August 20, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, BTIG Research started tracking the stock with Buy rating on March 20, 2025, and set its price target to $12. On January 02, 2025, Barclays initiated with a Overweight rating and assigned a price target of $16 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $14 on August 22, 2024. B. Riley Securities initiated its recommendation with a Buy and recommended $15 as its price target on July 25, 2024. Jefferies started tracking with a Buy rating for this stock on January 19, 2024, and assigned it a price target of $14. In a note dated February 24, 2023, Piper Sandler initiated an Overweight rating and provided a target price of $15 on this stock.
Orchestra BioMed Holdings Inc experienced fluctuations in its stock price throughout the past year between $2.20 and $6.50. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Orchestra BioMed Holdings Inc [NASDAQ: OBIO] shares were valued at $4.42 at the most recent close of the market. An investor can expect a potential return of 171.49% based on the average OBIO price forecast.
Analyzing the OBIO fundamentals
Trailing Twelve Months sales for Orchestra BioMed Holdings Inc [NASDAQ:OBIO] were 2.82M which represents -12.77% decline. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -24.21%, Pretax Profit Margin comes in at -23.67%, and Net Profit Margin reading is -23.67%. To continue investigating profitability, this company’s Return on Assets is posted at -1.63, Equity is -2.89 and Total Capital is -2.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.18 points at the first support level, and at 3.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.57, and for the 2nd resistance point, it is at 4.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Orchestra BioMed Holdings Inc [NASDAQ:OBIO] is 4.73. Also, the Quick Ratio is 4.72, while the Cash Ratio stands at 1.1. Considering the valuation of this stock, the price to sales ratio is 88.50, the price to book ratio is 5.71.
Transactions by insiders
Recent insider trading involved Aryeh Jason, Director, that happened on Sep 19 ’25 when 1000.0 shares were purchased. Director, Fain Eric S completed a deal on Aug 25 ’25 to buy 5760.0 shares. Meanwhile, Sherman Darren bought 3000.0 shares on Aug 25 ’25.
